Paraneoplastic sweating and fever are distinct pathophysiological processes, which might occur concurrently, whose treatment involves differing targets. While fever is usually caused by central hypothalamic reset in thermoregulatory mechanisms,PGE2 mediated and NSAID responsive, sweating which is mediated by an efferent sympathetic cholinergic response of eccrine glands, may occur as an independent phenomenon (separate from the expected defervescence following fever spontaneously or with antipyretics).

Proposed Step Ladder treatment

Step 1 – antipyretic – paracetamol or NSAID e.g. ibuprofen

Step 2 – antimuscarinic – amitriptyline (starting dose 25mg), propantheline (on empty stomach), hyoscine hydrobromide transdermal (to be changed every three days), glycopyrronium (200microgram-2mg PO t.d.s.)

Step 3 – gabapentin (hot flushes), H2-receptor antagonist (cimetidine), olanzapine (dopaminergic and adrenergic), propranolol (adrenergic), thalidomide.

Sweating that is secondary to opioid use is observed with the use of both morphine (additional histamine release) and methadone (predominantly serotonergic).

The unfavorable adverse effect profile of theophylline (painful peripheral neuropathy, deep venous thrombosis) limits its use in this setting, despite high response rates.

The diagnosis of paraneoplastic sweating requires the exclusion of following conditions – infection (naproxen test with sustained complete lysis), drug fever (including checkpoint inhibitor related), adrenal insufficiency, hyperthyroidism, thromboembolic disease, opioid-related sweating and hot flushes/menopause.

Positive indicators that might support a paraneoplastic etiology include temporal correlation between symptom and disease progression, pattern consistent with temporal profile of cytokine release, absence of localizing features, drenching sweats and tumor types with predisposition to this phenomenon (lymphoma, renal cell carcinoma, hepatocellular carcinoma).

References

Wilcock, A., Howard, P., Toller, C. S., Droney, J., & Charlesworth, S. (Eds.). (2025). Palliative care formulary (9th ed.). Pharmaceutical Press.

Zell, J.A., & Chang, J.C. (2005). Neoplastic fever: a neglected paraneoplastic syndrome. Supportive Care in Cancer, 13(11), 870–877. https://doi.org/10.1007/s00520-005-0825-4

Cheshire, W.P., & Fealey, R.D. (2008). Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Safety, 31(2), 109–126. https://doi.org/10.2165/00002018-200831020-00002

Yaksh, T.L., & Wallace, M.S. (2011). Opioids, analgesia, and pain management. In L. Brunton, B. Chabner, & B. Knollmann (Eds.), Goodman & Gilman’s Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill.

Disclaimer
Palliative medicine is a relatively young subspecialty whose intellectual and clinical boundaries continue to evolve. In the absence of definitive texts to address contemporary questions, artificial intelligence tools mainly Anthropic (Claude) have been employed to support deeper conceptual exploration, challenge assumptions, and improve clarity of expression. They do not replace critical scholarship, clinical experience, or editorial judgment. Final responsibility for all interpretations, factual accuracy, originality of synthesis, and the quality of the published material rests entirely with the Founder and Editor.